VBI Vaccines
ProfileJobs

VBI Vaccines

Suggest Edit
    • HealthcareTechnologybiotechhealthtechpharma
    VBI Vaccines, Inc. is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials.

    The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets.

    Revenue(FY, 2017)
    $865 K
    Market capitalization(2018-12-04)
    $101.7 M

    Employee Rating

    0More
    TypePublic
    HQCambridge, US
    Founded2001
    Size (employees)98 (est)+12%
    Websitevbivaccines.com
    VBI Vaccines was founded in 2001 and is headquartered in Cambridge, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    VBI Vaccines Office Locations

    VBI Vaccines has offices in Cambridge, Rehovot and Ottawa
    Cambridge, (HQ)
    2241 222 Third St
    Ottawa,
    201 310 Hunt Club Rd
    Rehovot,
    Derech Gad Feinstein
    Show all (3)
    Report incorrect company information

    VBI Vaccines Financials and Metrics

    VBI Vaccines Revenue

    VBI Vaccines 's revenue was reported to be $865 k in FY, 2017
    USD

    Revenue (Q3, 2018)

    		259.0k

    Gross profit (Q3, 2018)

    		(542.0k)

    Gross profit margin (Q3, 2018), %

    		(209.3%)

    Net income (Q3, 2018)

    		(15.4m)

    EBIT (Q3, 2018)

    		(14.5m)

    Market capitalization (4-Dec-2018)

    		101.7m

    Closing stock price (4-Dec-2018)

    		1.6

    Cash (30-Sep-2018)

    		26.0m
    VBI Vaccines 's current market capitalization is $101.7 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		548.0k865.0k

    Cost of goods sold

    		3.7m5.2m

    Gross profit

    		(3.1m)(4.3m)

    Gross profit Margin, %

    		(570%)(500%)
    Quarterly
    USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Revenue

    		127.0k344.0k193.0k178.0k234.0k259.0k

    Cost of goods sold

    		1.3m1.4m1.3m1.4m1.1m801.0k

    Gross profit

    		(1.1m)(1.0m)(1.1m)(1.2m)(833.0k)(542.0k)

    Gross profit Margin, %

    		(904%)(294%)(591%)(694%)(356%)(209%)
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		6.7m12.6m32.3m67.7m

    Accounts Receivable

    		10.0k143.0k

    Inventories

    		830.0k788.0k

    Current Assets

    		34.4m70.4m
    Quarterly
    USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Cash

    		23.5m15.6m10.1m58.1m41.1m26.0m

    Accounts Receivable

    		43.0k226.0k203.0k167.0k172.0k124.0k

    Inventories

    		959.0k895.0k701.0k783.0k1.0m1.1m

    Current Assets

    		25.8m18.8m13.0m60.4m44.9m30.2m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(1.5m)(14.4m)(13.9m)(23.2m)(39.0m)

    Depreciation and Amortization

    		18.9k606.0k730.0k

    Inventories

    		(93.0k)(89.0k)

    Accounts Payable

    		11.0k(675.0k)
    Quarterly
    USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Net Income

    		(8.6m)(17.7m)(27.5m)(12.3m)(29.0m)(44.3m)

    Depreciation and Amortization

    		171.0k353.0k539.0k149.0k288.0k417.0k

    Inventories

    		(78.0k)17.0k198.0k(286.0k)(373.0k)

    Accounts Payable

    		(609.0k)49.0k614.0k946.0k1.3m
    show all
    USDY, 2018

    Financial Leverage

    		1.4 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Alnylam Pharmaceuticals
    Healthcare - Public
    Sorrento Therapeutics
    Healthcare - Public
    Pernix Therapeutics
    Healthcare - Public
    Microbiome Therapeutics
    Healthcare - Private
    Compare competitors

    VBI Vaccines Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    VBI Vaccines News and Updates

    November 09, 2018

    VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update

    ­­
    October 24, 2018

    VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)

    CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that initial clinical data from the Phase 1/2a study of VBI-1901 in…
    September 26, 2018

    VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

    CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SA…
    September 16, 2018

    VBI Vaccines Responds to Unfounded Allegations in Globes Article

    CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali Weinreb (the “Article”) alleging that VBI failed to meet its responsibilities …
    Report incorrect company information

    VBI Vaccines Company Life and Culture

    Report incorrect company information
    Download PDF

     VBI Vaccines Frequently Asked Questions

    • When was VBI Vaccines founded?

      VBI Vaccines was founded in 2001.

    • How many employees does VBI Vaccines have?

      VBI Vaccines has 98 employees.

    • What is VBI Vaccines revenue?

      Latest VBI Vaccines annual revenue is $865 k.

    • What is VBI Vaccines revenue per employee?

      Latest VBI Vaccines revenue per employee is $8.8 k.

    • Who are VBI Vaccines competitors?

      Competitors of VBI Vaccines include Alnylam Pharmaceuticals, Sorrento Therapeutics and Pernix Therapeutics.

    • Where is VBI Vaccines headquarters?

      VBI Vaccines headquarters is located at 2241 222 Third St, Cambridge.

    • Where are VBI Vaccines offices?

      VBI Vaccines has offices in Cambridge, Rehovot and Ottawa.

    • How many offices does VBI Vaccines have?

      VBI Vaccines has 3 offices.